Clinical Study of Escitalopram Oxalate Combined With taVNS in Depression and Concomitant Inflammatory Symptoms
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This study is expected to include 90 patients with major depressive disorder and rheumatoid
arthritis as study subjects.Randomly divided into 3 groups: drug + VNS stimulation group,
drug + sham stimulation group and drug group, each group had 30 patients.The treatment period
of each group was 8 weeks.Age and sex were matched in all three groups.Scale evaluation and
inflammatory factor test were performed before treatment (baseline), at week 4 and week 8
after treatment.Head MRI, evoked potential, and electrocardiogram were performed at baseline
and at the end of week 8.